pargyline has been researched along with Disease Exacerbation in 4 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression." | 1.42 | Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. ( Guo, J; He, L; Jiang, G; Liu, X; Wang, M; Wang, Z; Weng, X, 2015) |
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 2 |
| Liu, X | 2 |
| Jiang, G | 2 |
| Chen, H | 1 |
| Guo, J | 2 |
| Weng, X | 2 |
| Wang, Z | 1 |
| He, L | 1 |
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Eberling, JL | 1 |
| Bankiewicz, KS | 1 |
| Jordan, S | 1 |
| VanBrocklin, HF | 1 |
| Jagust, WJ | 1 |
4 other studies available for pargyline and Disease Exacerbation
| Article | Year |
|---|---|
Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
Topics: Cadherins; Carcinoma; Cell Line, Tumor; Disease Progression; Histone Demethylases; Humans; Male; Neo | 2015 |
Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; | 2015 |
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
PET studies of functional compensation in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Progression; Dopamin | 1997 |